Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (7 quarters reported)
$63.4M in Q4 2024 → $127M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Tyra Biosciences Inc | 95.9% | Unchanged | 3,823,425 | $122M |
| Vir Biotechnology Inc | 4.1% | Unchanged | 509,917 | $5.2M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 6 quarters.
quarter ended June 30, 2026 · filed July 22, 2026
No position changes this quarter.
quarter ended March 31, 2026 · filed April 21, 2026
No position changes this quarter.
quarter ended December 31, 2025 · filed January 13, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Tyra Biosciences Inc | Trimmed | −256,871 | −$6.75M | 97.0% |
quarter ended September 30, 2025 · filed November 07, 2025
No position changes this quarter.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Allakos Inc | Exited | −2,546,147 | −$580K | — |
| Vir Biotechnology Inc | Added | +8,000 | +$40.3K | 6.2% |
quarter ended March 31, 2025 · filed May 12, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Vir Biotechnology Inc | Added | +12,432 | +$80.6K | 7.8% |
Loading...
